Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Down 0.1% – Here’s What Happened

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) shares fell 0.1% on Monday . The company traded as low as $10.59 and last traded at $10.60. 240,459 shares were traded during mid-day trading, an increase of 686% from the average session volume of 30,578 shares. The stock had previously closed at $10.61.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Drugs Made In America Acquisition currently has an average rating of “Sell”.

Drugs Made In America Acquisition Price Performance

The business’s fifty day simple moving average is $10.55 and its 200-day simple moving average is $10.45.

Drugs Made In America Acquisition (NASDAQ:DMAA) last posted its earnings results on Thursday, May 14th. The company reported $0.06 EPS for the quarter.

Institutional Trading of Drugs Made In America Acquisition

A number of institutional investors and hedge funds have recently bought and sold shares of DMAA. Quarry LP bought a new stake in Drugs Made In America Acquisition during the 3rd quarter valued at about $161,000. Sandia Investment Management LP bought a new stake in shares of Drugs Made In America Acquisition in the third quarter worth approximately $161,000. Lineage Point Capital LP bought a new stake in shares of Drugs Made In America Acquisition in the fourth quarter worth approximately $330,000. Shaolin Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition in the second quarter worth approximately $1,020,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Drugs Made In America Acquisition in the third quarter worth approximately $1,024,000.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.